All stock lists
Oruka Therapeutics, Inc. (NASDAQ:ORKA)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
92.89+12.74 (+15.90%)
Insider Score
––Not scored
ORKA Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ORKA Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 43.00 K | 43.00 K | 28.00 K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -43.00 K | -43.00 K | -28.00 K | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 6.81 M | 7.25 M | 6.76 M | 5.12 M | 4.34 M | 5.16 M |
| R&D Expense | 43.26 M | 29.14 M | 27.64 M | 28.99 M | 24.09 M | 19.93 M |
| Operating Expenses | 50.06 M | 36.39 M | 34.40 M | 34.10 M | 28.43 M | 25.09 M |
| Operating Income | -50.11 M | -36.43 M | -34.43 M | -34.10 M | -28.43 M | -25.09 M |
| Pretax Income | -41.21 M | -31.82 M | -29.58 M | -30.28 M | -24.57 M | -21.00 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -41.21 M | -31.82 M | -29.58 M | -30.28 M | -24.57 M | -21.00 M |
| EPS (Basic) | -0.66 | -0.58 | -0.54 | -0.69 | -0.58 | -0.50 |
| EPS (Diluted) | -0.66 | -0.58 | -0.54 | -0.69 | -0.58 | -0.50 |
| Shares Outstanding | 62.87 M | 55.17 M | 54.42 M | 44.07 M | 42.23 M | 41.68 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.